Skip to main content
. 2020 Oct 30;9(6):756–770. doi: 10.1159/000510299

Fig. 1.

Fig. 1

Survival outcomes according to the patterns of tumor enhancement on CT scans prior to the introduction of lenvatinib. PFS rate (a), PPS rate (b), and OS rate (c). PFS, progression-free survival; PPS, post-progression survival; OS, overall survival.